Literature DB >> 16849644

Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.

Maria Luigia Randi1, Maria Caterina Putti, Margherita Scapin, Enrica Pacquola, Fabio Tucci, Concetta Micalizzi, Luigi Zanesco, Fabrizio Fabris.   

Abstract

Essential thrombocythemia (ET) is rare in children, and little or no information is available about clonality or JAK2 mutations. However, the analyses in this work prove useful for the diagnosis of adult myeloproliferative disorders (MPDs). We evaluated the clonality status and V617FJAK2 mutation in 20 children affected by ET and compared them with 47 consecutive adult ET cases. Clonality was evaluated on the DNA of granulocytes and on the RNA of platelets. V617FJAK2 was analyzed by sequencing tests, allele-specific polymerase chain reaction (PCR), and digestion by BsaXI. A monoclonal pattern was found in 4 (28.5%) of 14 children and in 45% of informative adults. Heterozygous V617FJAK2 was found less frequently in children than in adults (P < .009). Only 2 girls showed both the V617FJAK2 mutation and a monoclonal pattern; one of them was the only child presenting a major thrombotic complication. In contrast to adults, most children with ET do not show either a clonal disorder or the V617FJAK2 mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849644     DOI: 10.1182/blood-2006-04-014746

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Mutational profile of childhood myeloproliferative neoplasms.

Authors:  A Karow; R Nienhold; P Lundberg; E Peroni; M C Putti; M L Randi; R C Skoda
Journal:  Leukemia       Date:  2015-07-30       Impact factor: 11.528

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Authors:  Vikas Dua; Satya Prakash Yadav; Vijay Kumar; Renu Saxena; Anupam Sachdeva
Journal:  Int J Hematol       Date:  2012-10-07       Impact factor: 2.490

Review 4.  Essential thrombocythemia: past and present.

Authors:  Fabrizio Fabris; Maria Luigia Randi
Journal:  Intern Emerg Med       Date:  2009-07-28       Impact factor: 3.397

5.  Myeloproliferative Neoplasms in Children.

Authors:  Inga Hofmann
Journal:  J Hematop       Date:  2015-08-02       Impact factor: 0.196

6.  Asymtomatic essential thrombocythemia in a child: a rare case report.

Authors:  Majid Vafaie; Kaveh Jaseb; Majid Ghanavat; Mohamad Pedram; Tooran Rahiminia
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

7.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Authors:  Jean-Christophe Ianotto; Natalia Curto-Garcia; Marie Lauermanova; Deepti Radia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 8.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 9.  Human growth disorders associated with impaired GH action: Defects in STAT5B and JAK2.

Authors:  Vivian Hwa
Journal:  Mol Cell Endocrinol       Date:  2020-10-27       Impact factor: 4.102

10.  Essential Thrombocythemia in Children: A Retrospective Study.

Authors:  Muhammed Ameen; Khawar Siddiqui; Saadiya Khan; Mahasen Saleh; Abdullah Al-Jefri; Abdulrahman Al-Musa
Journal:  J Hematol       Date:  2021-06-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.